These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
582 related articles for article (PubMed ID: 34020723)
1. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study. Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723 [TBL] [Abstract][Full Text] [Related]
2. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590 [TBL] [Abstract][Full Text] [Related]
3. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report. Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828 [TBL] [Abstract][Full Text] [Related]
4. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304 [TBL] [Abstract][Full Text] [Related]
5. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562 [TBL] [Abstract][Full Text] [Related]
7. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748 [TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
9. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834 [TBL] [Abstract][Full Text] [Related]
10. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion. Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300 [TBL] [Abstract][Full Text] [Related]
11. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis. Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851 [TBL] [Abstract][Full Text] [Related]
12. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma. Andrews C; Prayson RA Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004 [TBL] [Abstract][Full Text] [Related]
14. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification. Ammendola S; Broggi G; Barresi V Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583 [TBL] [Abstract][Full Text] [Related]
15. Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors. Kitahama K; Iijima S; Sumiishi A; Hayashi A; Nagahama K; Saito K; Sasaki N; Kobayashi K; Shimizu S; Nagane M; Shibahara J Brain Tumor Pathol; 2021 Jan; 38(1):23-29. PubMed ID: 32989606 [TBL] [Abstract][Full Text] [Related]
16. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542 [TBL] [Abstract][Full Text] [Related]
17. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. Sathornsumetee S; Cheunsuchon P; Sangruchi T World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282 [TBL] [Abstract][Full Text] [Related]
18. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement. Kang KM; Song J; Choi Y; Park C; Park JE; Kim HS; Park SH; Park CK; Choi SH Radiology; 2024 May; 311(2):e233120. PubMed ID: 38713025 [TBL] [Abstract][Full Text] [Related]
19. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas. Yang X; Lin Y; Xing Z; She D; Su Y; Cao D Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488 [TBL] [Abstract][Full Text] [Related]
20. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. de Biase D; Acquaviva G; Visani M; Marucci G; De Leo A; Maloberti T; Sanza V; Di Oto E; Franceschi E; Mura A; Ragazzi M; Serra S; Froio E; Bisagni A; Brandes AA; Pession A; Tallini G J Mol Diagn; 2021 Sep; 23(9):1185-1194. PubMed ID: 34186176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]